{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:42:38Z","timestamp":1790206958621,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00059-020-04904-4","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T07:03:00Z","timestamp":1582786980000},"page":"267-271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Amyloid cardiomyopathy","Kardiale Manifestation bei Amyloidosen"],"prefix":"10.1007","volume":"45","author":[{"given":"Arnt V.","family":"Kristen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"issue":"21","key":"4904_CR1","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"M Gertz","year":"2015","unstructured":"Gertz\u00a0M, Benson\u00a0MD, Dyck\u00a0PJ (2015) Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J\u00a0Am Coll Cardiol 66(21):2451\u20132466","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"4904_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/qjmed\/91.2.141","volume":"91","author":"SW Dubrey","year":"1998","unstructured":"Dubrey\u00a0SW, Cha\u00a0K, Anderson\u00a0J et al (1998) The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. Qjm 91(2):141\u2013157","journal-title":"Qjm"},{"key":"4904_CR3","doi-asserted-by":"publisher","first-page":"E60","DOI":"10.1002\/ajh.23936","volume":"90","author":"E Kastritis","year":"2015","unstructured":"Kastritis\u00a0E, Roussou\u00a0M, Gavriatopoulou\u00a0M et al (2015) Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. Am J Hematol 90:E60\u201365","journal-title":"Am J Hematol"},{"issue":"3","key":"4904_CR4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","volume":"40","author":"M Tanskanen","year":"2008","unstructured":"Tanskanen\u00a0M, Peuralinna\u00a0T, Polvikoski\u00a0T et al (2008) Senile systemic amyloidosis affects 25\u202f% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 40(3):232\u2013239","journal-title":"Ann Med"},{"issue":"9","key":"4904_CR5","doi-asserted-by":"publisher","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","volume":"12","author":"MS Maurer","year":"2019","unstructured":"Maurer\u00a0MS, Bokhari\u00a0S, Damy\u00a0T et\u00a0al (2019) Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Heart Fail 12(9):e6075","journal-title":"Heart Fail"},{"issue":"13","key":"4904_CR6","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","volume":"120","author":"C Rapezzi","year":"2009","unstructured":"Rapezzi\u00a0C, Merlini\u00a0G, Quarta\u00a0CC et\u00a0al (2009) Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 120(13):1203\u20131212","journal-title":"Circulation"},{"issue":"24","key":"4904_CR7","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"J Gillmore","year":"2016","unstructured":"Gillmore\u00a0J, Maurer\u00a0MS, Falk\u00a0R et\u00a0al (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133(24):2404\u20132412","journal-title":"Circulation"},{"issue":"2","key":"4904_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer\u00a0MS, Mazen\u00a0H, Grogan\u00a0M et\u00a0al (2016) Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J\u00a0Am Coll Cardiol 68(2):161\u2013172","journal-title":"J Am Coll Cardiol"},{"key":"4904_CR9","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","volume":"33","author":"PT Sattianayagam","year":"2012","unstructured":"Sattianayagam\u00a0PT, Hahn\u00a0AF, Whelan\u00a0CJ et\u00a0al (2012) Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart\u00a0J 33:1120\u20131127","journal-title":"Eur Heart J"},{"issue":"11","key":"4904_CR10","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.recesp.2017.05.018","volume":"70","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2019","unstructured":"Gonz\u00e1lez-L\u00f3pez\u00a0E, L\u00f3pez-Sainz\u00a0A, Garcia-Pavia\u00a0P (2019) Diagnosis and treatment of transthyretin cardiac amyloidosis. Progress and hope. Rev Esp Cardiol 70(11):991\u20131004","journal-title":"Rev Esp Cardiol"},{"key":"4904_CR11","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","volume":"119","author":"D Feng","year":"2009","unstructured":"Feng\u00a0D, Syed\u00a0IS, Martinez\u00a0M et\u00a0al (2009) Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 119:2490\u20132497","journal-title":"Circulation"},{"key":"4904_CR12","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3324\/haematol.2013.095463","volume":"99","author":"G Palladini","year":"2014","unstructured":"Palladini\u00a0G, Milani\u00a0P, Foli\u00a0A et al (2014) Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a\u00a0risk-adapted approach. Haematologica 99:743\u2013750","journal-title":"Haematologica"},{"key":"4904_CR13","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1038\/leu.2014.227","volume":"28","author":"G Palladini","year":"2014","unstructured":"Palladini\u00a0G, Milani\u00a0P, Foli\u00a0A et\u00a0al (2014) Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a\u00a0matched case\u2013control study on 174 patients. Leukemia 28:2311\u20132316","journal-title":"Leukemia"},{"key":"4904_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16198","author":"B Lilleness","year":"2019","unstructured":"Lilleness\u00a0B, Doros\u00a0G, Ruberg\u00a0FL, Sanchorawala\u00a0V (2019) Establishment of brain natriuretic peptide\u2014based criteria for evaluating cardiac response to treatment in light-chain amyloidosis. J\u00a0Haematol. https:\/\/doi.org\/10.1111\/bjh.16198","journal-title":"J Haematol"},{"issue":"9","key":"4904_CR15","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","volume":"99","author":"BG Ericzon","year":"2015","unstructured":"Ericzon\u00a0BG, Wilczek\u00a0HE, Larsson\u00a0M et\u00a0al (2015) Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 99(9):1847\u20131854","journal-title":"Transplantation"},{"issue":"3","key":"4904_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1177\/1526924817715463","volume":"27","author":"D Banerjee","year":"2017","unstructured":"Banerjee\u00a0D, Roeker\u00a0LE, Grogan\u00a0M et\u00a0al (2017) Outcomes of patients with familial transthyretin amyloidosis after liver transplantation. Prog Transplant 27(3):246\u2013250","journal-title":"Prog Transplant"},{"issue":"3","key":"4904_CR17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","volume":"24","author":"FA Barroso","year":"2017","unstructured":"Barroso\u00a0FA, Judge\u00a0DP, Ebede\u00a0B et al (2017) Long-term safety and efficacy of\u00a0tafamidis\u00a0for the treatment of hereditary\u00a0transthyretin\u00a0amyloid polyneuropathy: results up to 6 years. Amyloid 24(3):194\u2013204","journal-title":"Amyloid"},{"issue":"12","key":"4904_CR18","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1111\/ene.12225","volume":"20","author":"P Lozeron","year":"2013","unstructured":"Lozeron\u00a0P, Th\u00e9audin\u00a0M, Mincheva\u00a0Z et\u00a0al (2013) French network for FAP (CORNAMYL). Effect on disability and safety of\u00a0tafamidis\u00a0in late onset of Met30\u00a0transthyretin\u00a0familial amyloid polyneuropathy. Eur J Neurol 20(12):1539\u20131545","journal-title":"Eur J Neurol"},{"issue":"6","key":"4904_CR19","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","volume":"6","author":"G Merlini","year":"2013","unstructured":"Merlini\u00a0G, Plant\u00e9-Bordeneuve\u00a0V, Judge\u00a0DP et al (2013) Effects of tafamidis on\u00a0transthyretin\u00a0stabilization and clinical outcomes in patients with non-Val30Met\u00a0transthyretin\u00a0amyloidosis. J\u00a0Cardiovasc Transl Res 6(6):1011\u20131020","journal-title":"J Cardiovasc Transl Res"},{"key":"4904_CR20","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer\u00a0MS, Schwartz\u00a0JH, Gundapaneni\u00a0B et\u00a0al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N\u00a0Engl J Med 379:1007\u20131016","journal-title":"N Engl J Med"},{"issue":"24","key":"4904_CR21","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"Berk\u00a0JL, Suhr\u00a0OB, Obici\u00a0L et\u00a0al (2013) Repurposing diflunisal for familial amyloid polyneuropathy: a\u00a0randomized clinical trial. Diflunisal\u00a0trial consortium. JAMA 310(24):2658\u20132667","journal-title":"JAMA"},{"key":"4904_CR22","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1208760","volume":"369","author":"T Coelho","year":"2013","unstructured":"Coelho\u00a0T, Adams\u00a0D, Silva\u00a0A et\u00a0al (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N\u00a0Engl J Med 369:819\u2013829","journal-title":"N Engl J Med"},{"key":"4904_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams\u00a0D, Gonzalez-Duarte\u00a0A, O\u2019Riordan\u00a0WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N\u00a0Engl J Med 379:11\u201321","journal-title":"N Engl J Med"},{"key":"4904_CR24","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon\u00a0SD, Adams\u00a0D, Kristen\u00a0A et al (2019) Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Analysis of the APOLLO study. Circulation 139:431\u2013443","journal-title":"Circulation"},{"key":"4904_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson\u00a0MD, Waddington-Cruz\u00a0M, Berk\u00a0JL et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N\u00a0Engl J Med 379:22\u201331","journal-title":"N Engl J Med"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-020-04904-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-020-04904-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-020-04904-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T01:34:57Z","timestamp":1614303297000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-020-04904-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["4904"],"URL":"https:\/\/doi.org\/10.1007\/s00059-020-04904-4","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]},"assertion":[{"value":"27 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"A.V.\u00a0Kristen points out the following relationships. AlnylamPharmaceuticals: study investigator (APOLLO, APOLLO OLE, ENDEAVOUR, HELIOS-A, HELIOS-B), advisory boards, travel support, honoraria. AkceaTherapeutics: travel support, honoraria, advisory boards. IONIS Pharmaceuticals: study investigator (NEURO-TTR), advisory board. PfizerInc.\/Pharma GmbH: study investigator (THAOS registry, ATTR-ACT, ATTR-ACT OLE), research support (ASPIRE 2015), member of THAOS\nScientific Board and advisory boards, travel support, honoraria.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}